Medplus Health Services Ltd (MEDPLUS) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management revised full-year FY27 EBITDA guidance down to 3,800-4,000 million, citing an unexpected 840 million annual impact from wage hikes.
- Previously discussed capex plans for wellness and concierge services are officially withdrawn; the sole focus is now on store openings and private label growth.
- Management aims for a 0.5% to 0.75% cost reduction over four quarters via warehouse consolidation and automation to offset margin pressures.
Performance Overview
- Achieved net addition of 166 stores during the quarter, bringing the total network to 5,642 stores.
- Consolidated revenue grew to 20,371 million with an operating EBITDA margin of 4.8%.
- Private label sales contributed 21.4% to total revenues, with non-pharma private label sales growing 18% quarter-on-quarter.
- Gross margins improved to 25.1% from 24.5% in the previous quarter, driven by a better private label mix and lower discounts.
- The diagnostics business showed strong performance, with revenue growing to 410.5 million and EBITDA margins reaching 23.8%.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.